1.Sagan, D, Margulis, L. Garden of Microbial Delights: A Practical Guide to the Subvisible World. Boston, MA: Harcourt Brace Jovanovich, Inc, Publishers; 1988:74.
2.McGowan, JE Jr.Minimizing antimicrobial resistance in hospital bacteria: can switching or cycling drugs help? Infect Control Hosp Epidemiol 1986;7:573–576.
3.Wise, R, Hart, T, Cars, O, Streulens, M, Helmuth, R, Huovinen, P, et al. Antimicrobial resistance. Is a major threat to public health. BMJ 1998;317:609–610.
4.Gerberding, JL, McGowan, JE Jr, Tenover, FC. Emerging nosocomial infections and antimicrobial resistance. Curr Clin Top Infect Dis 1999;19:83–98.
5.Shlaes, DM, Gerding, DN, John, JF Jr, Craig, WA, Bornstein, DL, Duncan, RA, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997;18:275–291.
6.John, JF Jr, Fishman, NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997;24:471–485.
7.Service, RF. Antibiotics that resist resistance. Science 1995:270:724–727.
8.Knowles, DJ. New strategies for antibacterial drug design. Trends Microbiol 1997;5:379–383.
9.Betts, RF, Valenti, WM, Chapman, SW, Chonmaitree, T, Mowrer, G, Pincus, P, et al. Five-year surveillance of aminoglycoside usage in a university hospital. Ann Intern Med 1984;100:219–222.
10.Gerding, DN. Antimicrobial cycling: lessons learned from the aminoglycoside experience. Infect Control Hosp Epidemiol 2000;21 (suppl):S12–S17.
11.Gerding, DN, Larson, TA, Hughes, RA, Weiler, M, Shanholtzer, C, Peterson, LR. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother 1991;35:1284–1290.
12.Gerding, DN, Larson, TA. Aminoglycoside resistance in gram-negative bacilli during increased amikacin use. Comparison of experience in 14 United States hospitals with experience in the Minneapolis Veterans Administration Medical Center. Am J Med 1985;79:1–7.
13.Archibald, L, Phillips, L, Monnet, D, McGowan, JE Jr, Tenover, F, Gaynes, R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997;24:211–215.
14.Fridkin, SK, Edwards, JR, Pichette, SC, Pryor, ER, McGowan, JE Jr, Tenover, FC, et al. Determinants of vancomycin use in adult intensive care units in 41 Unites States hospitals. Clin Infect Dis 1999;28:1119–1125.
15.Hiramatsu, K, Aritaka, N, Hanaki, H, Kawasaki, S, Hosada, Y, Hori, S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350:1670–1673.
16.Lavin, BS. Antibiotic cycling and marketing into the 21st century: a perspective from the pharmaceutical industry. Infect Control Hosp Epidemiol 2000;21 (suppl) :S32–S35.
17.Kollef, MH, Vlasnik, J, Sharpless, L, Pasque C, Murphy, D, Fraser, V. Scheduled change of antibiotic classes. A strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997;156(4 pt 1):1040–1048.
18.Landman, D, Chockalingam, M, Quale, JM. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in hospital antibiotic formulary. Clin Infect Dis 1998;28:1062–1066.
19.Bradley, SJ, Wilson, ALT, Allen, MC, Sher, HA, Goldstone, AH, Scott, GM. The control of hyperendemic glycopeptide-resistant Enterococcus spp on a haematology unit by changing antibiotic usage. J Antimicrob Chemother 1999;43:261–266.
20.Dominguez, EA, Smith, TL, Reed, E, Sanders, CC, Sanders, WE Jr. A pilot study of antibiotic cycling in a hematology-oncology unit. Infect Control Hosp Epidemiol 2000;21(suppl):S4–S8.
21.Hyatt, JM, Schentag, JJ. Potential role of pharmacokinetics, pharmacodynamics, and computerized databases in controlling bacterial resistance. Infect Control Hosp Epidemiol 2000;21(suppl):S18–S21.
22.Arbeit, RD. Laboratory procedures for the epidemiologic analysis of microorganisms. In: Murray, PR, Baron, EJ, Pfaller, MA, Tenover, FC, Yolken, RH, eds. Manual of Clinical Microbiology. Washington, DC: American Society for Microbiology Press; 1999:125–137.
23.Bonhoeffer, S, Lipsitch, M, Levin, BR. Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci U S A 1997;94:12106–12111.
24.McGowan, JE Jr.Strategies for study of the role of cycling on antimicrobial use and resistance. Infect Control Hosp Epidemiol 2000;21 (suppl):S36–S43.
25.John, JF Jr, Rice, LB. The microbial genetics of antibiotic cycling. Infect Control Hosp Epidemiol 2000;21(suppl):S22–S31.
26.Hall, RM, Collis, CM. Antibiotic resistance in gram-negative bacteria: the role of gene cassettes and integrons. Drug Resistance Updates 1999;1:109–119.